Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

BETHESDA, Md., March 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it is regaining from its partner MedImmune the rights in North America to its most advanced BiTE antibody candidate, blinatumomab, also known as MT103. In Europe, Micromet is conducting a phase 2 clinical trial with blinatumomab for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. In addition, the two companies plan to initiate a research program for the development of a new BiTE antibody for the treatment of hematological cancers. Micromet also announced its financial results for the fourth quarter and full year ended December 31, 2008.

"We had a successful 2008 and are excited about the prospects for 2009. Our lead BiTE antibody program blinatumomab reported encouraging clinical data from phase 1 and phase 2 clinical trials last year, which form the basis for advancing the program towards its first pivotal clinical trial. We are pleased to regain North American rights to blinatumomab from our partner and are looking forward to taking control of the worldwide development of the program," stated Christian Itin, President and Chief Executive Officer of Micromet. "With our successful financing and partnering activities last year and early this year, we are well positioned to move our programs to the next value step."

Recent Developments relating to Blinatumomab and Micromet's Collaboration with MedImmune:

In March 2009, MedImmune elected to return its license rights to blinatumomab to Micromet. Micromet will assume responsibility for the worldwide clinical development
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
(Date:7/31/2014)... Although RNA-Sequencing is a relatively ... analyses appearing around 2008, RNA-Sequencing has rapidly evolved ... In the last several years, assays have improved ... smaller input amounts, process degraded RNA, and perform ... the bioinformatics side, there have been improvements in ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN ... Cancer News. , Bill Bro, KCA CEO, says, “We’re ... an international news organization. When we began using iReport last ... month’s program highlights news of an enzyme that is lost ... study. Kidney Cancer News also presents a report on outcomes ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... 1, 2011 Life Technologies Corporation (Nasdaq: ... webcasting management presentations to investors as part of the ... which is being held at the company,s headquarters in ...  Mark Stevenson, Life Technologies, President and Chief Operating Officer, ...
... NEW YORK, March 1, 2011 NeoStem, Inc. (NYSE Amex: ... in the U.S. and China, announced today that Dr. Robert ... Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been ... 6th Annual New York Stem Cell Summit. The Summit will ...
... BioNeutral Group, Inc. (OTC Bulletin Board: ... announced that its wholly-owned subsidiary, BioNeutral Services, Inc., has ... (KEDFA) to receive up to $280,000 in development incentives ... February 24 meeting, six companies, including BioNeutral Services, Inc., ...
Cached Biology Technology:Life Technologies to Webcast Investor Presentation as Part of the UBS West Coast Life Sciences & Diagnostics Bus Trip 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 3Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 4BioNeutral Group to Receive Economic Development Incentives 2BioNeutral Group to Receive Economic Development Incentives 3
(Date:7/31/2014)... marine noise can affect animal movement and communication, with ... and Exeter and the cole Pratique des Hautes tudes ... stops embryonic development and increases larval mortality in sea ... Stylocheilus striatus used in this study) usually hatch ... on toxic alga but this study, conducted in a ...
(Date:7/30/2014)... at New York University is paving the way ... in civilians and military troops exposed to poisonous ... , An article in the current issue of ... in detoxifying organophosphates, which are compounds commonly used ... was developed by NYU School of Engineering Associate ...
(Date:7/30/2014)... in Lewis Carroll,s Through the Looking Glass, collaborators ... of Singapore improved a 35-year-old ecology model to ... millions of years. , The new model, called ... "Red Queen Effect," an evolutionary hypothesis introduced by ... that organisms must constantly increase their fitness (or ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... likely impact of ocean acidification on shellfish and other marine ... is published this week (date) in the journal Global ... because some of the increased carbon dioxide humans are adding ... water to produce an acid. The results suggest that ...
... by the National Science Foundation (NSF) found state agency ... fiscal year 2009, a 7 percent increase over the ... details nationwide and state-by-state totals of R&D activities performed ... first time survey data are available by individual state ...
... release is available in German . Tomato ... with a genetic defect that made the fruits mature very slowly, ... were delighted as it gave them more time to transport the ... it would be sold. At the stores, the tomatoes could then ...
Cached Biology News:New study helps predict impact of ocean acidification on shellfish 2New study helps predict impact of ocean acidification on shellfish 3Ethylene of no effect -- why peppers do not mature after picking 2
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... all plate washing needs in both the 384-well ... 384 provides an excellent solution for a variety ... development, Screening or Lead Optimization) and Research. ... 384 has set a standard for ultra-fast washing ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: